Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Porsteinsson · SciRah

Researcher profile · Semantic Scholar

A. Porsteinsson

Share profile

A. Porsteinsson — researcher profile on SciRah

h-index: 51
Works: 255
Citations: 12K

Most-cited papers

Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
A. Porsteinsson, R. Isaacson, S. Knox, M. Sabbagh +1 more
2021The journal of prevention of Alzheimer's disease682 citations Open access
Semantic Scholar
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
M. Tolar, S. Abushakra, J. Hey, A. Porsteinsson +1 more
2020Alzheimer's Research & Therapy299 citations Open access
Semantic Scholar
Early Detection of Mild Cognitive Impairment (MCI) in Primary Care
M. Sabbagh, Mercè Boada, S. Borson, M. Chilukuri +10 more
2020The journal of prevention of Alzheimer's disease185 citations Open access
Semantic Scholar
Diagnostic criteria for apathy in neurocognitive disorders
David S. Miller, P. Robert, L. Ereshefsky, L. Adler +23 more
2021Alzheimer's & Dementia166 citations Open access
Semantic Scholar
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
J. Mintzer, K. Lanctôt, R. Scherer, P. Rosenberg +11 more
2021JAMA Neurology106 citations Open access
Semantic Scholar
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction
Xiao-Pu Zhou, Yu Chen, Fanny C. F. Ip, Yuanbing Jiang +322 more
2023Communications Medicine60 citations Open access
Semantic Scholar
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment
Paul Monroe Butler, Jenny Yang, Roland Brown, Matthew Hobbs +28 more
2025Nature Medicine58 citations Open access
Semantic Scholar
Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease
M. T. Duong, Sandhitsu R. Das, Xueying Lyu, Long Xie +286 more
2022Nature Communications44 citations Open access
Semantic Scholar
Neurobiologic Rationale for Treatment of Apathy in Alzheimer’s Disease With Methylphenidate
C. van Dyck, A. Arnsten, Prasad R. Padala, O. Brawman‐Mintzer +9 more
2020The American journal of geriatric psychiatry43 citations Open access
Semantic Scholar
APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
S. Abushakra, A. Porsteinsson, M. Sabbagh, L. Bracoud +6 more
2020Alzheimer's & Dementia36 citations Open access
Semantic Scholar
Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer’s disease
William T. Hu, T. Ozturk, Alexander L. Kollhoff, W. Wharton +168 more
2021Nature Communications30 citations Open access
Semantic Scholar
A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer’s disease
Ying Zhang, Le Xue, Shuoyan Zhang, Jiacheng Yang +309 more
2024Alzheimer's Research & Therapy27 citations Open access
Semantic Scholar
APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics
S. Abushakra, A. Porsteinsson, Marwan N. Sabbagh, David Watson +9 more
2024Alzheimer's & Dementia26 citations Open access
Semantic Scholar
iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer’s disease
Cristina Zivko, Ram Sagar, Ariadni Xydia, Alejandro Lopez-Montes +6 more
2024Molecular Psychiatry25 citations Open access
Semantic Scholar
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
S. Abushakra, A. Power, David Watson, A. Porsteinsson +16 more
2025Drugs21 citations Open access
Semantic Scholar
Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force
Maria Soto, P. Rosenberg, C. Ballard, B. Vellas +99 more
2023The journal of prevention of Alzheimer's disease21 citations Open access
Semantic Scholar
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease
Daniel Lee, E. Clark, Inga M. Antonsdottir, A. Porsteinsson
2023Expert Opinion on Pharmacotherapy20 citations
Semantic Scholar
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial
K. Coleman, Scott Berry, J. Cummings, G. Hsiung +23 more
2025Lancet Neurology19 citations Open access
Semantic Scholar
Effect of online tDCS to left somatomotor cortex on neuropsychiatric symptoms among older adults at risk for dementia
Adam Turnbull, Mia Anthony, D. Tadin, A. Porsteinsson +2 more
2022Cortex; a journal devoted to the study of the nervous system and behavior19 citations Open access
Semantic Scholar
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
D. Angioni, O. Hansson, R. Bateman, C. Rabe +99 more
2023The journal of prevention of Alzheimer's disease18 citations Open access
Semantic Scholar
Targeting autonomic flexibility to enhance cognitive training outcomes in older adults with mild cognitive impairment: study protocol for a randomized controlled trial
F. V. Lin, K. Heffner, R. Gevirtz, Zheng-Wu Zhang +2 more
2021Trials18 citations Open access
Semantic Scholar
Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial
T. Rajji, S. Baksh, D. Shade, Zahinoor Ismail +7 more
2025Nature Medicine17 citations Open access
Semantic Scholar
Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies
A. Spira, V. Zipunnikov, R. Raman, Jiyoon Choi +13 more
2021SLEEP Advances15 citations Open access
Semantic Scholar
Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer’s disease: an exploratory study of ^18F-FDG-PET
Qi Zhang, Chunqiu Fan, Lu-Yao Wang, Tao-Ran Li +306 more
2023GeroScience13 citations Open access
Semantic Scholar
Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease.
Daniel Lee, E. Clark, Inga M. Antonsdottir, A. Porsteinsson
2024Journal of the American Medical Directors Association12 citations
Semantic Scholar
ATTITUDES TOWARD COMPUTERS MODERATE THE EFFECT OF COMPUTERIZED COGNITIVE TRAININGS IN OLDEST-OLD SENIOR LIVING CENTER RESIDENTS
F. Lin, Kaylin Cottone, Kelsey McDermott, A. Jacobs +3 more
2020The American journal of geriatric psychiatry11 citations Open access
Semantic Scholar
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials
S. Abushakra, P. Doraiswamy, J. Hey, D. Tosun +25 more
2025CNS Drugs10 citations Open access
Semantic Scholar
Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease
Jeffrey L. Cummings, S. Cohen, J. Murphy, Holly M. Brothers +13 more
2025Alzheimer's & Dementia9 citations Open access
Semantic Scholar
Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer’s disease: a novel small molecule with disease modifying potential
Daniel Lee, Inga M. Antonsdottir, E. Clark, A. Porsteinsson
2024Expert Opinion on Pharmacotherapy9 citations
Semantic Scholar
Alzheimer's Disease Drug Development
Jeffrey L. Cummings, J. Kinney, H. Fillit, K. Brunden +122 more
20229 citations Open access
Semantic Scholar
Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer’s disease: A factor analysis
S. Hendrix, Mary Sano, Constantine G. Lyketsos, P. Rosenberg +4 more
2025International Psychogeriatrics8 citations Open access
Semantic Scholar
A US-based practitioner’s guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer’s dementia – recommendations of an expert, multispecialty advisory panel
George T. Grossberg, Angela Sanford, C. Montano, A. Porsteinsson +4 more
2025Postgraduate medicine8 citations Open access
Semantic Scholar
Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease
Yuqi Qiu, Diane M. Jacobs, Karen Messer, D. Salmon +61 more
2025Alzheimer's Research & Therapy6 citations Open access
Semantic Scholar
Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
K. Lanctôt, Luc Rivet, Shankar Tumati, J. Perin +14 more
2022The American journal of geriatric psychiatry6 citations
Semantic Scholar
Measuring apathy in Alzheimer’s disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): a comparison of instruments
K. Lanctôt, Roberta W. Scherer, Abby Li, D. Vieira +12 more
2020The American journal of geriatric psychiatry6 citations Open access
Semantic Scholar
Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease
James W Kupiec, A. Porsteinsson, Raymond S. Turner, S. Hendrix +8 more
2026The journal of prevention of Alzheimer's disease5 citations Open access
Semantic Scholar
Local molecular and connectomic contributions of tau-related neurodegeneration
F. Nabizadeh, Michael W. Weiner, P. Aisen, Ronald Petersen +300 more
2024GeroScience4 citations Open access
Semantic Scholar
Escitalopram for Agitation in Alzheimer’s Dementia
T. Rajji, S. Baksh, D. Shade, Z. Ismail +7 more
2024Alzheimer's & Dementia4 citations Open access
Semantic Scholar
Prevalence of Amyloid-Related Imaging Abnormalities in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Findings from Ongoing Clinical Trials of Oral Anti-Amyloid Agent ALZ-801 (Valiltramiprosate) (P5-6.003)
S. Abushakra, R. Mandelbaum, J. Barakos, P. Scheltens +10 more
2023Monday, April 244 citations
Semantic Scholar
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
E. Clark, J. Perin, N. Herrmann, O. Brawman‐Mintzer +9 more
2023Alzheimer's & Dementia4 citations Open access
Semantic Scholar
ALZ‐NET: Using Real World Evidence to Inform the Future of Alzheimer’s Treatment and Care
G. Rabinovici, M. Rafii, C. Apgar, Na An +23 more
2022Alzheimer's & Dementia4 citations
Semantic Scholar
Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders.
K. Sankhe, K. Bawa, D. Miller, D. Bateman +11 more
2025International Psychogeriatrics3 citations Open access
Semantic Scholar
Measuring clinically relevant change in apathy symptoms in ADMET & ADMET 2
S. Tumati, N. Herrmann, J. Perin, Paul B. Rosenberg +10 more
2024International Psychogeriatrics3 citations Open access
Semantic Scholar
Adverse Effects of Methylphenidate for Apathy in Patients with Alzheimer’s Disease (ADMET2 Trial)
Lijuan Zeng, J. Perin, A. Gross, D. Shade +11 more
2024International Journal of Geriatric Psychiatry3 citations
Semantic Scholar
Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world
H. Snyder, M. Tampi, P. Aisen, R. Allegri +33 more
2026Alzheimer's & Dementia2 citations Open access
Semantic Scholar
Peripheral biomarkers associated with apathy and predicting response to methylphenidate: secondary analysis of the ADMET2 study
K. Sankhe, M. Ruthirakuhan, A. Andreazza, O. Brawman‐Mintzer +14 more
2026International Psychogeriatrics2 citations Open access
Semantic Scholar
Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation
Maansi Barnwal, S. Baksh, Zahinoor Ismail, D. Shade +5 more
2026Alzheimer's & Dementia2 citations Open access
Semantic Scholar
Results of SIGNAL‐AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with mild Alzheimer’s dementia
E. Siemers, Elizabeth E. Evans, T. Fisher, M. Boise +20 more
2024Alzheimer's & Dementia2 citations Open access
Semantic Scholar
The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) — A Fundamental Ally in AD Prevention Research
A. Porsteinsson, E. Clark
2020The journal of prevention of Alzheimer's disease2 citations Open access
Semantic Scholar
Proteomic profiling of brain organoids and extracellular vesicles identifies early Alzheimer's disease biomarkers and drug response heterogeneity
Rachel J. Boyd, Dai-Yun Dong, Ram Sagar, A. Iliuk +7 more
2026Alzheimer's & Dementia1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Mintzer×18
Invite
J. Mintzer — researcher profile on SciRah
C. van Dyck×16
Invite
C. van Dyck — researcher profile on SciRah
A. Levey×14
Invite
A. Levey — researcher profile on SciRah
K. Lanctôt×10
Invite
K. Lanctôt — researcher profile on SciRah

×10

Invite

P. Aisen — researcher profile on SciRah

O. Brawman‐Mintzer×9

Invite

O. Brawman‐Mintzer — researcher profile on SciRah

S. Abushakra×8

Invite

S. Abushakra — researcher profile on SciRah

Invite

R. Doody — researcher profile on SciRah

Invite

M. Mintun — researcher profile on SciRah

P. Doraiswamy×8

Invite

P. Doraiswamy — researcher profile on SciRah

Invite

M. Farlow — researcher profile on SciRah

Invite

S. Salloway — researcher profile on SciRah